Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Baiwen Li

Matched on ORCID iD 0000-0002-4245-8832; OpenAlex author ID A5102705206. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper

Papers 9

  1. Contribution of a Circulating 2'-O-methylated MicroRNA Panel to the Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.91716↗
  2. Identification of m7G-Related LncRNA Signature for Predicting Prognosis and Evaluating Tumor Immune Infiltration in Pancreatic Adenocarcinoma. Last author DOI 10.3390/diagnostics13101697↗
  3. Suppression of Wnt/β-catenin Signaling in PDAC via METTL16-mediated N6-methyladenosine Modification of DVL2. Last author DOI 10.7150/jca.85860↗
  4. Circular RNA circ_0047744 suppresses the metastasis of pancreatic ductal adenocarcinoma by regulating the miR-21/SOCS5 axis. Last author DOI 10.1016/j.bbrc.2022.03.082↗
  5. Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes. Co-author DOI 10.3389/fgene.2022.919638↗
  6. RELA-induced MiR-21 Exerts Oncogenic Effects on PDAC via Targeting of ARHGAP24. Last author DOI 10.7150/jca.73690↗
  7. miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2. Last author DOI 10.1038/s41419-018-1182-9↗
  8. miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. First author DOI 10.3892/or.2015.3945↗
  9. Net expression inhibits the growth of pancreatic ductal adenocarcinoma cell PL45 in vitro and in vivo. Co-author DOI 10.1371/journal.pone.0057818↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lanting Yu · 6 shared papers, 2018–2023 · strength 0.98
  2. Ni Xie · 5 shared papers, 2022–2023 · strength 0.89
  3. Haoran Xie · 3 shared papers, 2022 · strength 0.48
  4. Qiuyan Zhao · 3 shared papers, 2018–2022 · strength 0.40
  5. Xingpeng Wang · 3 shared papers, 2013–2023 · strength 0.38
  6. Jiawei Lu · 1 shared paper, 2023 · strength 0.22
  7. Xuejiao Wu · 1 shared paper, 2024 · strength 0.22
  8. Zilin Yang · 1 shared paper, 2024 · strength 0.22
  9. Weiyan Yao · 1 shared paper, 2024 · strength 0.22
  10. Li Cheng · 1 shared paper, 2022 · strength 0.16
  11. Xinjian Wan · 2 shared papers, 2013–2015 · strength 0.09
  12. Zhonglin Zhu · 1 shared paper, 2018 · strength 0.09
  13. Mingjie Jiang · 1 shared paper, 2018 · strength 0.09
  14. Lei Li · 1 shared paper, 2015 · strength 0.05
  15. Chen Huang · 1 shared paper, 2015 · strength 0.05
  16. Xiangjun Meng · 1 shared paper, 2013 · strength 0.03
  17. Lei Li · 1 shared paper, 2013 · strength 0.03
  18. Duanmin Hu · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.